Enfortumab vedotin and MMAE disposition
A reduced ADC–payload disposition model linking enfortumab vedotin concentration to formation and elimination of the released MMAE payload and their cumulative exposures.
- Therapeutic
- Enfortumab vedotin
- Target
- PVRL4, Nectin-4
- Disease
- Nectin-4-positive cancers and MMAE drug–drug interaction assessment
Biological model
A reduced ADC–payload disposition model linking enfortumab vedotin concentration to formation and elimination of the released MMAE payload and their cumulative exposures.
Intervention
Enfortumab vedotin
Biological focus
PVRL4, Nectin-4
Context
Nectin-4-positive cancers and MMAE drug–drug interaction assessment
Model details
A reduced ADC–payload disposition model linking enfortumab vedotin concentration to formation and elimination of the released MMAE payload and their cumulative exposures.
Modeled states
- adc conc ug mlug/mL
Modeled dynamic state for adc conc ug ml.
- auc adc ug day mlug*day/mL
Modeled dynamic state for auc adc ug day ml.
- auc mmae ng day mlng*day/mL
Modeled dynamic state for auc mmae ng day ml.
- elapsed dayday
Modeled dynamic state for elapsed day.
- mmae conc ng mlng/mL
Modeled dynamic state for mmae conc ng ml.
Key readouts
- Enfortumab vedotin concentrationug/mL
Model-derived readout for enfortumab vedotin concentration.
- MMAE concentrationng/mL
Model-derived readout for mmae concentration.
- Cumulative ADC exposureug*day/mL
Model-derived readout for cumulative adc exposure.
- Cumulative MMAE exposureng*day/mL
Model-derived readout for cumulative mmae exposure.
- elapsed dayday
Model-derived readout for elapsed day.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
EV 1.25 mg/kg single dose reduced
How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure? Explore this intervention regimen through Enfortumab vedotin concentration, MMAE concentration, Cumulative ADC exposure, Cumulative MMAE exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure?
adc decay day
Model parameter controlling adc decay day.
Exploratory range around the default value.
5 evenly spaced values in 1/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotinJournal of Pharmacokinetics and Pharmacodynamics
